Oliver W. Gramlich, PhD, provides an in-depth discussion about the pathobiology and visual phenotype of immune-mediated optic neuropathies.

Multiple sclerosis (MS), neuromylitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) all feature distinct clinicopathologic phenotypes. These phenotypes will be highlighted in relevant preclinical models of optic neuritis by utilizing highly translational functional and structural measurements of vision.

The webinar features an introduction of relevant animal models, and explains pertinent experimental techniques ranging from behavioral assessment of visual acuity (VA) with the OptoDrum, to electrophysiology recordings via pattern electroretinography (pERG) and visual evoked potential (VEP) recordings, to structural imaging of the retina with optical coherence tomography (OCT).

Key Topics Include:

  • Introduce the clinical relevance and pathobiology of optic neuritis
  • Familiarize the audience with novel, autoantibody-induced in vivo models of NMOSD and MOGAD optic neuritis
  • Recap of the MOG-induced experimental autoimmune encephalomyelitis (EAE) optic neuritis model
  • Summarize translational methods of visual function and structure (VA, pERG, VEP, OCT) for preclinical drug testing

Who Should Attend?

Researchers working in the field of vision science, multiple sclerosis-related optic neuritis and glaucoma, neuroimmunology, and neuroinflammation.

Presenters

Research Assistant Professor
Ophthalmology and Visual Sciences
The University of Iowa

Oliver Gramlich studied Biology and Neurobiology at the University of Mainz followed by a PhD focusing on Experimental Ophthalmology. He then started a position at the University of Iowa where he is now working as Research Assistant Professor at the Department of Ophthalmology and Visual Sciences. Besides his research efforts on Multiple Sclerosis-related optic neuritis and glaucoma, he is currently establishing a model of Neuromyelitis optica in order to help establish reliable preclinical models that faithfully reproduce visual impairment as seen in patients.

Register

Striatech Journal Club - November 9, 2022
Tell us more about yourself:
Consent Policy *

Production Partner

Striatech

Striatech is a young biotech company that spun off from the University of Tübingen, Germany, at the beginning of 2018. The founders – a team of neurobiologists – are all experienced vision researchers and have made it their common goal to make innovative ideas and products from vision and behavioral research accessible to scientists worldwide.

Additional Content From Striatech

Related Content